AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04514237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02640846
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
Trial: NCT01236612
Drug: Malarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Trial: NCT00782418
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
Trial: NCT04393584
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: d1 Leucovorin 200 mg/m² every two weeks
Trial: NCT04137276
Drug: vitamin C, vitamin B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
Trial: NCT01337531
Drug: Gonal-F, Fostimon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form
Trial: NCT01337531
Drug: Gonal-F, Fostimon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection, daily, 10-15 days
Trial: NCT01178853
Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Trial: NCT02870790
Drug: TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one pill daily
Trial: NCT00048594
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04087421
Drug: Glycerol OBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppository. Stimulates the rectum and softens and loosens stool.
Trial: NCT01438749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01438749
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses (3 dose levels)
Trial: NCT01515995
Drug: Nebulized magnesium sulfate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
Trial: NCT01163253
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral BID
Trial: NCT01163253
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral BID
Trial: NCT00005986
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00543569
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Trial: NCT00905307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06531447
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 21 days 4 cycles
Trial: NCT06531447
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 21 days 4 cycles
Trial: NCT01682837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
Trial: NCT00898677
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to rizatriptan
Trial: NCT04121728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
Trial: NCT04697758
Drug: AXT107 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.1 mg/eye
Trial: NCT04697758
Drug: AXT107 0.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.25 mg/eye
Trial: NCT04697758
Drug: AXT107 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.5 mg/eye
Trial: NCT01316926
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Trial: NCT01316926
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Trial: NCT01629329
Drug: Aspirin, Acetaminophen, Caffeine pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
Trial: NCT03871647
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perioperative beta blockers
Trial: NCT01365000
Drug: NKTR118 Formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT01365000
Drug: NKTR118 Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT01365000
Drug: NKTR118 Formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT00148733
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Trial: NCT00590018
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
Trial: NCT00590018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5 days intravenously.
Trial: NCT03016442
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Trial: NCT03523832
Drug: Celecoxib and Pregabaline
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose versus repetition dose
Trial: NCT00000271
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Trial: NCT00131040
Drug: Aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01519245
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
Trial: NCT00136747
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04436224
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
Trial: NCT02222220
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01410188
Drug: OPA-6566
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
Trial: NCT00710424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Trial: NCT00178490
Drug: High blood pressure treatment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
Trial: NCT04638790
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 i.v. day 1,15 for ABVD/AVD
Trial: NCT01410188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
Trial: NCT00647777
Drug: Zyprexa® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fed
Trial: NCT00952289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets were administered as oral doses in the same manner as active drug.
Trial: NCT04638790
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 i.v. day 1 for EACODD-14
Trial: NCT04638790
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m2 i.v. day 1
Trial: NCT00645398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Trial: NCT02517372
Drug: CRD007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02586636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
Trial: NCT00011765
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01474330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00605241
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00820768
Drug: ABI-010
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-AAG and ABI-007
Trial: NCT03746860
Drug: Tablet, Dispersible
RxNorm normalized name: TABLET, DISPERSIBLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/day with 12 SQ-HDM per lyo-tablet
Trial: NCT03809182
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
Trial: NCT01225640
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg twice daily (BID) for 14 days
Trial: NCT01225640
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg once daily (QD) for 14 days
Trial: NCT01734161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo receive 50cc normal saline
Trial: NCT03375112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
Trial: NCT00332748
Drug: Oral Taxane
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03921268
Drug: AZD1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
Trial: NCT02876055
Drug: Local Infiltration Analgesia (LIA)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
Trial: NCT00777491
Drug: induction 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
Trial: NCT04160468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
Trial: NCT03987620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01790737
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03440216
Drug: blood sampling
RxNorm normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7
Trial: NCT03440216
Drug: Tissue sampling (lung)
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
Trial: NCT03859986
Drug: ALX-101 Gel Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALX-101 Gel Vehicle
Trial: NCT03859986
Drug: ALX-101 Gel 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALX-101 Gel 5%
Trial: NCT02597023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill with inert excipient, 1 time/day
Trial: NCT00484250
Drug: metronidazole,doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00321100
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
Trial: NCT02674737
Drug: tramadol and flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00603980
Drug: Inhaled placebo + oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato placebo + oral placebo
Trial: NCT00603980
Drug: Oral placebo qualifying session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualifying control session (oral placebo)
Trial: NCT00218036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
Trial: NCT04507438
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet administered daily for an 8 week period
Trial: NCT00654511
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1mcg/kg, Intravenous (IV)
Trial: NCT00654511
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2mcg/kg, Intravenous (IV)
Trial: NCT00115804
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
Trial: NCT01683071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
Trial: NCT03260205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
Trial: NCT01893242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to aleglitazar, once a day for approximately 3 years
Trial: NCT00649649
Drug: Accupril® Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fed
Trial: NCT03629418
Drug: Targeted blood-pressure management
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
Trial: NCT03629418
Drug: Routine blood-pressure management
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
Trial: NCT01793051
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
Trial: NCT01972880
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04534439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
Trial: NCT03226080
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered as a placebo in equal volume for the placebo group
Trial: NCT04439838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02854137
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
Trial: NCT02523313
Drug: Double Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Trial: NCT01830543
Drug: vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
Trial: NCT04433169
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT00625365
Drug: DEFINITY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert